ClinicalTrials.gg
CompletedNCT03462173Updated Mar 12, 2018

The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects

A Phase 1 interventional study of yimitasvir and placebo in Chronic Hepatitis c, sponsored by Sunshine Lake Pharma Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-12.

Sponsored by Sunshine Lake Pharma Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 2 months after the study started (first participant enrolled Dec 2014, registered Feb 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 44 studies in Hepatitis C, Chronic with a site in China — 2 open to participants now, 2 under way, none of them phase 3. Hepatitis C, Chronic · China.

Enrollment
26th of 34
32 · median 120
Started
2014
the only one that year
Phase 1
7 of 44
none open now
Registered
26th of 44
by date
Lead sponsor
7 of 44
Sunshine Lake Pharma Co., Ltd.

Among the 44 studies in Hepatitis C, Chronic with a site in China, this one is the 26th largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2014, is one of 7 in phase 1, and was the 26th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

2 of the 44 studies in Hepatitis C, Chronic with a site in China are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Hepatitis C, Chronic with a site in China, or all of them as a file.
02

Study summary

The Safety, Tolerability and Pharmacokinetic Study of Chronic Hepatitis C Treatment Drug Yimitasvir in Healthy Adults Subjects.

Read the detailed description

This was a Randomized,Double-blind, Placebo-controlled, Single Ascending Dose, Single-center Study to Assess the Safety, Tolerability and Pharmacokinetic of Yimitasvir in Healthy Adults Subjects

A total of 56 healthy subjects were divided into 7 groups, with each group consisting of 8 subjects. Six of the subjects received the investigational drug, and two received placebo. All of the subjects received a single dose.

03

Conditions studied

  • Chronic Hepatitis c

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, overall healthy subjects;
  • Between 18 and 45 years of age, inclusive, similar ages;
  • Body weight should be≥50 kg; (BMI) is between 19 and 25 kg/m2, inclusive, similar body weights;
  • Able to comprehend and sign the ICF voluntarily prior to initiate the study;
  • Able to communicate well with the investigator and complete the study according to the protocol.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing female, or plan for pregnancy within 6 months;
  • Female with positive urine pregnancy test results;
  • Positive test results for , anti- Ab, anti- Ab or syphilis;
  • Have taken any drug inhibiting gastric acid secretion within 1 month prior to study drug administration, such as: H2 receptor antagonists (eg: Cimetidine, Ranitidine, Famotidine, Nizatidine and Roxatidine); Proton pump inhibitors (eg: Omeprazole, Lansoprazole, Rabeprazole, Pantoprazole and Esomeprazole); cholinoceptor blocking drugs (eg: Atropine and Pirenzepine);
  • History of immune system disease (such as thymus disease);
  • Have undergone major surgery within 6 months before enrollment;
  • History of tumor;
  • Drink frequently within 6 months prior to study drug administration, namely alcohol consumption are more than 20 grams per day;
  • Smokers, who smoke more than 1 cigarettes/day within 3 months before the study;
  • Participated in any clinical trial within 3 months prior to the study;
  • Cannot be tolerant to oral drugs.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    30 mg single dose

    Healthy subjects, receiving a single dose of 30 mg yimitasvir(N=6) or placebo(N=2)

    Drug: yimitasvir · Drug: placebo

  • Experimental
    100 mg single dose

    Healthy subjects, receiving a single dose of 100 mg yimitasvir (N=6) or placebo(N=2)

    Drug: yimitasvir · Drug: placebo

  • Experimental
    200 mg single dose

    Healthy subjects, receiving a single dose of 200 mg yimitasvir (N=6) or placebo(N=2)

    Drug: yimitasvir · Drug: placebo

  • Experimental
    400 mg single dose

    Healthy subjects, receiving a single dose of 400 mg yimitasvir (N=6) or placebo(N=2)

    Drug: yimitasvir · Drug: placebo

  • Experimental
    600 mg single dose

    Healthy subjects, receiving a single dose of 600 mg yimitasvir (N=6) or placebo(N=2)

    Drug: yimitasvir · Drug: placebo

  • Experimental
    800 mg single dose

    Healthy subjects, receiving a single dose of 800 mg yimitasvir (N=6) or placebo(N=2)

    Drug: yimitasvir · Drug: placebo

  • Experimental
    1000 mg single dose

    Healthy subjects, receiving a single dose of 1000 mg yimitasvir (N=6) or placebo(N=2)

    Drug: yimitasvir · Drug: placebo

Interventions

  • Capsule administered orally once daily

    Also known as: DAG181

  • Drugplacebo

    Matching Placebo Capsule

    Also known as: DAG181 placebo

06

What researchers measure

Primary outcomes

  1. Adverse events

    To assess the safety and tolerability after a single dose of DAG181

    Time frame: Baseline to day 10

  2. Cmax

    Maximum observed plasma concentration of DAG181

    Time frame: Prior to dosing (0 h) and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 h after dosing

  3. Tmax

    Time of the maximum observed plasma concentration

    Time frame: Prior to dosing (0 h) and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 h after dosing

  4. AUC

    Area under the plasma concentration-time curve (AUC)

    Time frame: Prior to dosing (0 h) and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 h after dosing

  5. T1/2

    Terminal elimination half-life

    Time frame: Prior to dosing (0 h) and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 h after dosing

07

Study locations

1 site
  • Peking University First Hospital
    Beijing, Beijing 100034, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Jan 2015, 1 month.

Of 21 phase 1 interventional studies under Hepatitis C, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2018
First posted
Mar 12, 2018
StartActual
Dec 3, 2014
Primary completionActual
Jan 30, 2015
CompletionActual
Jan 22, 2016
Last update
Mar 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03462173
Responsible party
Sponsor
First posted
Mar 12, 2018
Start date
Dec 3, 2014
Primary completion
Jan 30, 2015
Completion
Jan 22, 2016
Last update
Mar 12, 2018

Study contacts

Yimin Cui, Doctor
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Yimitasvir

Start the discussion